PANORAMIC

So, although this study is still recruiting using the Paxlovid drug, the results have now been published for the part of the study where Molnupiravir drug was used. The aim of the study was to see if using these medications would reduce hospitalisations and mortality rates. With Molnupiravir, 26,288 patients were recruited to the study with 12,821 taking Molnupiravir and the rest not taking. Recruitment was from the 8/12/21 until 27/4/22 with the mean age of patients being 56, 58.6% of them female and 98.9% of them had had at least 1 covid vaccine. 

After 28 days, out of the patients taking the Molnupiravir, 102 were hospitalised with 2 dying. Out of the patients not taking it, 93 were hospitalised with 5 dying. 

For recovery times, it was taking an average of 9 days for people to recover from Covid who were taking the Molnupiravir compared with an average of 15 days for people to recover from Covid who weren't taking it. 

They also conducted a viral sub-study which showed that people taking Molnupiravir has less viral load. 

So, summary of the results was that taking Molnupiravir did not reduce hospital admissions and mortality rates in vaccinated individuals but did result in earlier recovery from the virus and reduced healthcare seeing in primary care services.

It was also the largest randomised trial of community-based treatment for Covid in the World!